Jing Li1, Jian Gu2. 1. College of Pharmacy, Southwest University for Nationalities, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan, 610041, People's Republic of China. 27918716@qq.com. 2. College of Pharmacy, Southwest University for Nationalities, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan, 610041, People's Republic of China.
Abstract
PURPOSE: We performed a meta-analysis to systematically review the gastrointestinal (GI) events (diarrhea, nausea, vomiting, anorexia) of five newly approved (after 2011) VEGFR-TKIs in cancer patients. METHODS: The relevant studies of the randomized controlled trials (RCTs) in cancer patients treated with cabozantinib, vandetanib, lenvatinib, regorafenib, and axitinib were retrieved and the systematic evaluation was conducted. RESULTS: Forty-one randomized controlled trials and 10,860 patients were included. Current analysis suggested that the use of these agents increased the risk of all-grade and high-grade GI events, and the diarrhea was the most common GI events. The risk of all-grade and high-grade GI events varies significantly within drug types, tumor types, and VEGFR-TKIs-based regimens. CONCLUSION: The available data suggested that the use of the five newly approved VEGFR-TKIs may increase risk of GI events in cancer patients. Physicians and patients should be aware of these risks and frequent monitoring and careful management should be emphasized when managing these VEGFR-TKIs.
PURPOSE: We performed a meta-analysis to systematically review the gastrointestinal (GI) events (diarrhea, nausea, vomiting, anorexia) of five newly approved (after 2011) VEGFR-TKIs in cancerpatients. METHODS: The relevant studies of the randomized controlled trials (RCTs) in cancerpatients treated with cabozantinib, vandetanib, lenvatinib, regorafenib, and axitinib were retrieved and the systematic evaluation was conducted. RESULTS: Forty-one randomized controlled trials and 10,860 patients were included. Current analysis suggested that the use of these agents increased the risk of all-grade and high-grade GI events, and the diarrhea was the most common GI events. The risk of all-grade and high-grade GI events varies significantly within drug types, tumor types, and VEGFR-TKIs-based regimens. CONCLUSION: The available data suggested that the use of the five newly approved VEGFR-TKIs may increase risk of GI events in cancerpatients. Physicians and patients should be aware of these risks and frequent monitoring and careful management should be emphasized when managing these VEGFR-TKIs.
Authors: Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann Journal: BMJ Date: 2008-04-26
Authors: Matthew Smith; Johann De Bono; Cora Sternberg; Sylvestre Le Moulec; Stéphane Oudard; Ugo De Giorgi; Michael Krainer; Andries Bergman; Wolfgang Hoelzer; Ronald De Wit; Martin Bögemann; Fred Saad; Giorgio Cruciani; Antoine Thiery-Vuillemin; Susan Feyerabend; Kurt Miller; Nadine Houédé; Syed Hussain; Elaine Lam; Jonathan Polikoff; Arnulf Stenzl; Paul Mainwaring; David Ramies; Colin Hessel; Aaron Weitzman; Karim Fizazi Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: C Twelves; E Chmielowska; L Havel; S Popat; A Swieboda-Sadlej; P Sawrycki; P Bycott; A Ingrosso; S Kim; J A Williams; C Chen; A J Olszanski; P de Besi; J H Schiller Journal: Ann Oncol Date: 2014-01 Impact factor: 32.976
Authors: Brian I Rini; Yoshihiko Tomita; Bohuslav Melichar; Takeshi Ueda; Viktor Grünwald; Mayer N Fishman; Hirotsugu Uemura; Mototsugu Oya; Angel H Bair; Glen I Andrews; Brad Rosbrook; Eric Jonasch Journal: Clin Genitourin Cancer Date: 2016-04-22 Impact factor: 2.872
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Katalin Boér; István Láng; Antonio Llombart-Cussac; Inger Andreasson; Guillermo L Vivanco; Nick Sanders; Gillian M Pover; Elizabeth Murray Journal: Invest New Drugs Date: 2010-09-10 Impact factor: 3.850
Authors: Toni K Choueiri; Robert W Ross; Susanna Jacobus; Ulka Vaishampayan; Evan Y Yu; David I Quinn; Noah M Hahn; Thomas E Hutson; Guru Sonpavde; Stephanie C Morrissey; Geoffrey C Buckle; William Y Kim; Daniel P Petrylak; Christopher W Ryan; Mario A Eisenberger; Amir Mortazavi; Glenn J Bubley; Mary-Ellen Taplin; Jonathan E Rosenberg; Philip W Kantoff Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: John V Heymach; Luis Paz-Ares; Filippo De Braud; Martin Sebastian; David J Stewart; Wilfried E E Eberhardt; Anantbhushan A Ranade; Graham Cohen; Jose Manuel Trigo; Alan B Sandler; Philip D Bonomi; Roy S Herbst; Annetta D Krebs; James Vasselli; Bruce E Johnson Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Joseph Aisner; Judith B Manola; Shaker R Dakhil; Philip J Stella; Mika A Sovak; Joan H Schiller Journal: J Thorac Oncol Date: 2013-08 Impact factor: 15.609